Drugs / S95011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04605978 | Aug 2021 → Jan 2023 | Sjogren syndrome | Servier | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S95011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04605978 ↗ |
| Route | Intravenous | “IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.” NCT04605978 ↗ |